量研学術機関リポジトリ「QST-Repository」は、国立研究開発法人 量子科学技術研究開発機構に所属する職員等が生み出した学術成果(学会誌発表論文、学会発表、研究開発報告書、特許等)を集積しインターネット上で広く公開するサービスです。 Welcome to QST-Repository where we accumulates and discloses the academic research results(Journal Publications, Conference presentation, Research and Development Report, Patent, etc.) of the members of National Institutes for Quantum Science and Technology.
Thank you very much for using our website. On the 11th of March 2019, this site was moved from our own network server to the JAIRO Cloud network server. If you previously bookmarked this site, that bookmark will no longer work. We would be grateful if you could bookmark the website again. Thank you very much for your understanding and cooperation.
Purpose: To estimate the toxicity and efficacy of carbon ion radiotherapy for skull base and paracervical
tumors in clinical trials.
Patients and Methods: A phase I/II dose escalation study for skull base and paracervical tumors was initiated in
April 1997. The patients were treated with 16 fractions for 4 weeks with a total dose of 48.0, 52.8, 57.6, or
60.8Gy equivalents (GyE). In April of 2004, a phase II study was initiated with an irradiation schedule of
60.8GyE in 16 fractions over four weeks. There were 76 patients included in the analysis. Histologically, 44
patients had chordoma, 12 chondrosarcoma, 9 olfactory neuroblastoma, 7 malignant meningioma, 1 giant cell
tumor, and 1 had a neuroendocrine carcinoma. The patients were treated with a dose of 48.0 GyE (4 patients),
52.8 GyE (6 patients), 57.6 GyE (9 patients) or 60.8 GyE (57 patients).
Results: The follow-up periods ranged from 3 to 158 months, with a median period of 46 months. At the time
of the analysis, there was no evidence of any serious acute (Grade ≥4 ) or late (Grade ≥3) reactions. The 5-year
local control and overall survival rates for all patients were 88% and 82%, respectively. The 5-year local control
and overall survival rates for chordoma patients were 88% and 87%, respectively.
Conclusion: A carbon ion dose of 60.8GyE in 16 fractions was effective and safe for the treatment of skull
base and paracervical tumors.
会議概要(会議名, 開催地, 会期, 主催者等)
2nd NIRS-ETOILE Joint Symposium on Carbon Ion Therapy